title: Safety monitoring of cardiac and hepatic systems in beta-thalassemia patients with chelating treatment in Taiwan.
abstract: We conducted a prospective 3-yr clinical study comparing deferiprone (L1) with desferrioxamine (DFX). The therapeutic efficacy and potential side-effects on cardiac and/or hepatic systems of thalassemia patients were assessed by left ventricular ejection fraction, T2-weighted magnetic resonance imaging, and biochemical parameters. In both groups, levels of serum ferritin decreased significantly, and the hepatic function improved notably. Besides decrement of iron, no marked pathohistological changes were observed in the liver biopsies. These results indicated that for patients who failed to respond to DFX treatment, the use of L1 to remove excess iron deposition is recommended.
authors.affiliation: Department of Paediatrics, China Medical College Hospital and Institute of Medical Sciences, China Medical College, Taichung, Taiwan. t6218@hpd.cmch.org.tw
authors.forename: Ching-Tien
authors.initials: CT
authors.lastname: Peng
authors.forename: Kuan-Chih
authors.initials: KC
authors.lastname: Chow
authors.forename: Jeon-Hor
authors.initials: JH
authors.lastname: Chen
authors.forename: Yi-Ping
authors.initials: YP
authors.lastname: Chiang
authors.forename: Tze-Yi
authors.initials: TY
authors.lastname: Lin
authors.forename: Chang-Hai
authors.initials: CH
authors.lastname: Tsai
mesh_terms: D000293:Adolescent; D000328:Adult; D015913:Chelation Therapy / Q000009:adverse effects / Q000379:methods*; D002648:Child; D000077543:Deferiprone; D003676:Deferoxamine / Q000627:therapeutic use / Q000633:toxicity; D005260:Female; D005293:Ferritins / Q000097:blood; D006801:Humans; D007501:Iron / Q000032:analysis; D007502:Iron Chelating Agents / Q000627:therapeutic use / Q000633:toxicity; D019190:Iron Overload / Q000150:complications / Q000188:drug therapy / Q000378:metabolism; D008111:Liver Function Tests; D008279:Magnetic Resonance Imaging; D008297:Male; D009206:Myocardium / Q000378:metabolism; D011728:Pyridones / Q000627:therapeutic use / Q000633:toxicity; D013318:Stroke Volume; D013624:Taiwan; D017086:beta-Thalassemia / Q000150:complications / Q000188:drug therapy* / Q000378:metabolism
chemical_list: D007502:Iron Chelating Agents; D011728:Pyridones; D000077543:Deferiprone; D005293:Ferritins; D007501:Iron; D003676:Deferoxamine